PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

Comparative Analysis of Adherence and Effectiveness Outcomes Between Rheumatoid Arthritis (RA) Patients Treated With Tofacitinib Modified Release (MR)

Completed

Conditions: Rheumatoid Arthritis

First Posted Date: 2019-07-12

Last Posted Date: 2024-04-03

Lead Sponsor: Pfizer

Target Recruit Count: 1057

Registration Number: NCT04018001

Locations: 🇺🇸
Pfizer, New York, New York, United States

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of PF-06651600 in Subjects With Hepatic Impairment and Healthy Volunteers

Phase 1

Completed

Conditions: Hepatic Impairment
Healthy Participants

Interventions: Drug: PF-06651600 30 mg

First Posted Date: 2019-07-11

Last Posted Date: 2021-04-08

Lead Sponsor: Pfizer

Target Recruit Count: 18

Registration Number: NCT04016077

Locations: 🇺🇸
University of Miami Division of Clinical Pharmacology, Miami, Florida, United States
🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States

Long-Term PF-06651600 for the Treatment of Alopecia Areata

Phase 3

Active, not recruiting

Conditions: Alopecia Areata

Interventions: Drug: PF-06651600
Biological: Tetanus and diphtheria toxoids and acellular pertussis (Tdap) vaccine
Biological: Meningococcal (groups A, C, W-135 and Y [ACWY]) oligosaccharide diphtheria CRM197 conjugate vaccine

First Posted Date: 2019-07-05

Last Posted Date: 2024-11-11

Lead Sponsor: Pfizer

Target Recruit Count: 1051

Registration Number: NCT04006457

Locations: 🇷🇺
FSBEI HE Russian University of Medicine of the MoH of Russia, Moscow, Russian Federation
🇺🇸
The University of Alabama at Birmingham Hosptial Outreach Lab, Birmingham, Alabama, United States
🇺🇸
The University of Alabama at Birmingham, Birmingham, Alabama, United States

and more 153 locations

Bioavailability Study of PF-06651600 Formulations in Healthy Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: PF-06651600

First Posted Date: 2019-07-02

Last Posted Date: 2019-11-01

Lead Sponsor: Pfizer

Target Recruit Count: 12

Registration Number: NCT04004663

Locations: 🇧🇪
Brussels Clinical Research Unit, Brussels, Be-bru, Belgium

Changes of Depression After First-year of Tofacitinib in RA Patients

Completed

Conditions: Rheumatoid Arthritis

First Posted Date: 2019-06-20

Last Posted Date: 2024-03-20

Lead Sponsor: Pfizer

Target Recruit Count: 73

Registration Number: NCT03992781

Locations: 🇨🇿
Revmatologicky ustav, Praha 2, Czechia
🇨🇿
Revmatologicke centrum s.r.o., Velke Bilovice, Czechia
🇨🇿
Mangala Hospital & Mangala Kidney Foundation, Karlovy Vary, Czechia

and more 5 locations

A 16 Week Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Type 2 Diabetes Mellitus

Phase 2

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Placebo
Drug: PF-06882961

First Posted Date: 2019-06-13

Last Posted Date: 2022-06-30

Lead Sponsor: Pfizer

Target Recruit Count: 412

Registration Number: NCT03985293

Locations: 🇺🇸
National Research Institute, Los Angeles, California, United States
🇺🇸
University Clinical Investigators, Incorporated, Tustin, California, United States
🇺🇸
Andres Patron D.O. P.A., Pembroke Pines, Florida, United States

and more 78 locations

IDentification of Factors Predictive of Tofacitinib's Survival in Patient With Rheumatoid Arthritis

Completed

Conditions: Arthritis, Rheumatoid

Interventions: Drug: Tofacitinib

First Posted Date: 2019-06-11

Last Posted Date: 2024-09-30

Lead Sponsor: Pfizer

Target Recruit Count: 314

Registration Number: NCT03981900

Locations: 🇫🇷
Cabinet Medical, Vincennes, France
🇫🇷
Centre Hospitalier D Auxerre, Auxerre, France
🇫🇷
Institut Calot Helio Marin, Berck Sur Mer, France

and more 49 locations

Evaluate Taste and Relative Bioavailability of Two Microsphere Formulations of Crizotinib in Healthy Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Treatment A
Drug: Treatment B
Drug: Treatment C
Drug: Treatment D
Drug: Treatment E
Drug: Treatment F
Drug: Treatment G
Drug: Treatment H

First Posted Date: 2019-06-06

Last Posted Date: 2019-11-15

Lead Sponsor: Pfizer

Target Recruit Count: 25

Registration Number: NCT03978143

Locations: 🇺🇸
Pfizer New Haven Clinical Research Unit, New Haven, Connecticut, United States

Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX

Completed

Conditions: Rheumatoid Arthritis

First Posted Date: 2019-06-05

Last Posted Date: 2023-06-09

Lead Sponsor: Pfizer

Target Recruit Count: 479

Registration Number: NCT03975790

Locations: 🇺🇸
Pfizer, New York, New York, United States

Singe Dose Study of PF- 06946860 in Healthy Adult Japanese Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Other: Placebo
Biological: PF-06946860

First Posted Date: 2019-06-05

Last Posted Date: 2020-01-29

Lead Sponsor: Pfizer

Target Recruit Count: 8

Registration Number: NCT03974776

Locations: 🇺🇸
Anaheim Clinical Trials LLC-Clinical Research, Anaheim, California, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy